{"url":"https://lda.senate.gov/api/v1/filings/a0346901-e178-427f-971e-4d0738bdd9a2/","filing_uuid":"a0346901-e178-427f-971e-4d0738bdd9a2","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2023,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a0346901-e178-427f-971e-4d0738bdd9a2/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John Green","dt_posted":"2023-07-19T19:42:43-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 North Capitol Street, NW, Suite 800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":400531586,"url":"https://lda.senate.gov/api/v1/registrants/400531586/","house_registrant_id":null,"name":"CROSSROADS STRATEGIES, LLC","description":"lobbying firm","address_1":"800 North Capitol Street, NW, Suite 800","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATHEW LAPINSKI","contact_telephone":"+1 202-559-0170","dt_updated":"2026-01-30T13:29:06.487633-05:00"},"client":{"id":55860,"url":"https://lda.senate.gov/api/v1/clients/55860/","client_id":55860,"name":"KAZMIRA LLC","general_description":"science-based manufacturer","client_government_entity":null,"client_self_select":false,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-05-15"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Regulatory issues related to CBD; Farm Bill Reauthorization.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":50936,"prefix":null,"prefix_display":null,"first_name":"HUNTER","nickname":null,"middle_name":null,"last_name":"MOORHEAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67932,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":null,"last_name":"GLEASON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143856,"prefix":"ms","prefix_display":"MS.","first_name":"IVELISSE","nickname":null,"middle_name":"ALEXANDRA","last_name":"PORROA-GARCIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67957,"prefix":null,"prefix_display":null,"first_name":"SALIM","nickname":null,"middle_name":null,"last_name":"ALAMEDDIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}